XERS News and Press, Xeris Pharmaceuticals Inc. From 04/18/23

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that the U.S. Patent and Trademark Office has issued US Paten...

--News Direct-- Xeris Biopharma chairman and CEO Paul Edick joins Proactive's Natalie Stoberman to share details behind its research evaluation collaboration with Regeneron Pharmaceuticals for further XeriJect development. Edick says the agreement will see Xeris using its proprietary drug...

2023-03-30 07:17:56 ET Xeris Biopharma Holdings ( NASDAQ: XERS ) announced Thursday an agreement with Regeneron Pharmaceuticals ( REGN ) to use its drug-formulation platform, XeriJect, to develop monoclonal antibodies for subcutaneous delivery. Per the terms, Chicago, ...

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapeutic areas, today announced that it has entered into a platform research evaluation collab...

Xeris Biopharma Holdings (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapeutic areas, appointed Ricki Fairley to its Board of Directors, increasing the size of the Board ...

2023-03-28 06:24:51 ET Summary Shares have lost over half their value during the past year. Commercial momentum appears to be building with management guiding for break-even cash flow by the end of 2023. Keveyis is facing generic competition in PPP and Recorlev is still in the...

2023-03-08 11:22:49 ET Xeris Biopharma ( NASDAQ: XERS ) stock fell ~10% on Wednesday despite Q4 results beating estimates. Net loss narrowed to -$12.93M, compared to -$50.79M in Q4 2021. Total revenue grew +54.6% to $33.14. Both top and bottom line surpassed analysts est...

2023-03-08 10:56:05 ET Xeris Biopharma Holdings, Inc. (XERS) Q4 2022 Earnings Conference Call March 8, 2023 8:30 A.M. ET Company Participants Allison Wey - Senior Vice President, Investor Relations, and Corporate Communications Paul Edick - Chairman and Chief Executi...

2023-03-08 06:25:58 ET Xeris Pharmaceuticals press release ( NASDAQ: XERS ): Q4 GAAP EPS of -$0.10 beats by $0.06 . Revenue of $32.54M (+52.3% Y/Y) beats by $1.5M . Cash, cash equivalents, and short-term investments at December 31, 2022 was $122.0 million compa...

Achieved fourth quarter net product revenue of $32.5M representing 52% growth compared to Q4 2021 Achieved full-year net product revenue of $109.3M representing 38% annual growth compared to 2021 on a pro forma basis Ended 2022 with $122.0M in cash, cash equivalents, and short-ter...